Last $61.28 USD
Change Today -0.24 / -0.39%
Volume 1.0M
DGX On Other Exchanges
New York
As of 8:04 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

quest diagnostics inc (DGX) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/11/13 - $64.10
52 Week Low
02/7/14 - $50.46
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for QUEST DIAGNOSTICS INC (DGX)

quest diagnostics inc (DGX) Related Businessweek News

View More BusinessWeek News

quest diagnostics inc (DGX) Details

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. It offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices; and risk assessment services for the life insurance industry. The company also develops, manufactures, and markets diagnostic products, including Simplexa molecular chemistries for testing infectious disease and hospital-acquired infections; HerpeSelect HSV serology; and DxSelect IFA and ELISA products for testing infectious diseases. In addition, it provides molecular diagnostic products in various segments, such as HIV-1 drug resistance testing under the ViroSeq brand name; and reproductive genetics and transplantation under the brand names of Atria and AlleleSeqr. Further, the company offers Care360 EHR, a solution that allows doctors to electronically create, manage, and distribute patient encounter notes, including vital signs and progress notes; and ChartMaxx, an electronic document management system for hospitals. The company offers its diagnostic information services to patients, physicians, hospitals, integrated delivery networks, health plans, employers, and others through a network of laboratories, patient service centers, and phlebotomists in physician offices. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Madison, New Jersey.

41,000 Employees
Last Reported Date: 02/18/14
Founded in 1967

quest diagnostics inc (DGX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $472.1K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $573.9K
Senior Vice President of Clinical Franchises
Total Annual Compensation: $520.0K
Senior Vice President and General Counsel
Total Annual Compensation: $492.1K
Compensation as of Fiscal Year 2013.

quest diagnostics inc (DGX) Key Developments

Quest Diagnostics Adds Vicky Gregg to Board of Directors

Quest Diagnostics announced that its board of directors has elected Vicky Gregg to serve as a director, effective immediately, expanding the Board to 10 members. Ms. Gregg served as the Chief Executive Officer of Chattanooga-based Blue Cross Blue Shield of Tennessee from 2003 through December 2012. Prior to being elected CEO, she served in a number of other leadership roles, including President and Chief Operating Officer. Before that, she held a series of senior roles at Humana Health Plans. Ms. Gregg is a noted national expert in health information technology and was appointed to the U.S. National Institutes of Health Commission on Systemic Interoperability in 2004.

Quest Diagnostics Announces Encouraging Data from Drug Abuse Study

Quest Diagnostics has announced data from a study which demonstrated decline in prescription drug misuse rates nationwide with multi-faceted drug abuse prevention programs. The findings suggest that broad, collaborative measures that include prescription drug databases and physician and patient education may be effective at curbing the nation's epidemic of prescription drug abuse. Florida, Georgia, Kentucky, New York and Tennessee showed the high rates of decline in misuse rates over the last three years, according to the study of more than 1.4 million drug test results between 2011 and 2013. The average decline for these states was 10.7%, nearly 2.5 times higher than the average decline of 4.4% for all other states combined, in the 46-state study. The Quest Diagnostics Health Trends study also found that 55% of Americans potentially put their health at risk by misusing their medications in 2013, a decrease of 8% points compared to misuse rates of 63% in 2011. All age groups and both genders were at risk of misuse, based on test results. The study's findings support previous research that suggests broad drug abuse approaches may be effective.

Sequenom Inc. and Quest Diagnostics Inc. Partner for Prenatal Diagnostic Test

Sequenom Inc. and Quest Diagnostics have announced an agreement under which Quest will offer national access to Sequenom Laboratories's noninvasive prenatal test, MaterniT21 PLUS laboratory-developed test, or LDT. Using a maternal blood sample, the noninvasive prenatal test (NIPT) analyzes chromosomal material in cell-free fetal DNA of pregnant women at increased risk for fetal chromosomal abnormalities. In addition, Quest has formed a license agreement with Sequenom for certain NIPT patents and patent applications. The license agreement is the first formed by Sequenom with a commercial lab in the US. Quest intends to use the intellectual property for the purposes of developing and validating its own proprietary lab-developed NIPT test.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DGX:US $61.28 USD -0.24

DGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Covance Inc $86.59 USD +0.34
Hologic Inc $25.59 USD +0.36
Laboratory Corp of America Holdings $105.63 USD +0.03
Myriad Genetics Inc $37.63 USD +0.46
QIAGEN NV €18.65 EUR +0.132
View Industry Companies

Industry Analysis


Industry Average

Valuation DGX Industry Range
Price/Earnings 11.5x
Price/Sales 1.2x
Price/Book 2.2x
Price/Cash Flow 9.8x
TEV/Sales 0.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUEST DIAGNOSTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at